IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management
Por:
Vega, P, Huguet, JM, Gómez, E, Rubio, S, Suarez, P, Vera, MI, Paredes, JM, Hernández-Camba, A, Plaza, R, Mañosa, M, Pajares, R, Sicilia, B, Madero, L, Kolterer, S, Leitner, C, Heatta-Speicher, T, Michelena, N, de Lamadrid, RS, Dignass, A and Gomollón, F
Publicada:
1 mar 2024
Ahead of Print:
1 ene 2024
Resumen:
BackgroundCrohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that contributes in part to irreversible bowel damage and long-term complications, reduced quality of life, invalidity, and economic burden. Suboptimal control of IBD is associated with higher healthcare resource utilization (HCRU), impaired quality of life (QoL), and reduced work productivity.AimsThe IBD-PODCAST study aimed to assess the proportion of IBD patients with suboptimal control and its associated impact.MethodsIBD-PODCAST is a cross-sectional, multicenter study that aimed to characterize the CD and UC population with optimal or suboptimal control according to the STRIDE-II criteria and patient- and physician-reported measures. Here we present the results of the Spanish cohort (n = 396).ResultsA total of 104/196 (53.1%) CD and 83/200 (41.5%) UC patients were found to have suboptimal disease control. Long-term treatment targets according to STRIDE-II were applied in 172 (87.8%) CD and 181 (90.5%) UC patients. 125 of 172 (72.7%) CD and 74 of 181 (40.9%) UC patients were currently treated with targeted immunomodulators. Patients with CD and UC and suboptimal disease control showed impaired QoL, higher HCRU and direct costs, and also loss of work productivity compared to those with optimal control.ConclusionDespite a high rate of targeted immunomodulator therapy, a substantial proportion of IBD patients show suboptimal disease control according to the STRIDE II criteria. Those patients with suboptimal disease control exhibit impaired QoL, less work productivity, and higher HCRU, suggesting that there is considerable need for better treatment approaches in IBD.
Filiaciones:
Vega, P:
Complejo Hosp Univ Ourense, Orense, Spain
Huguet, JM:
Hosp Gen Univ Valencia, Valencia, Spain
Gómez, E:
Hosp Univ Juan Ramon Jimenez, Huelva, Spain
Rubio, S:
Hosp Univ Navarra, Pamplona, Spain
Suarez, P:
Complejo Asistencial Univ Leon, Leon, Spain
Vera, MI:
Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
Paredes, JM:
Hosp Univ Dr Peset, Valencia, Spain
Hernández-Camba, A:
Hosp Univ Nuestra Senora Candelaria, Santa Cruz de Tenerife, Spain
Plaza, R:
Hosp Univ Infanta Leonor, Madrid, Spain
:
Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
CIBEREHD, Madrid, Spain
Pajares, R:
Hosp Univ Infanta Sofia, Madrid, Spain
Sicilia, B:
Hosp Univ Burgos, Burgos, Spain
Madero, L:
Hosp Gen Alicante, Serv Med Digest, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante, Spain
Kolterer, S:
AbbVie Inc, N Chicago, IL USA
Leitner, C:
AbbVie Inc, N Chicago, IL USA
Heatta-Speicher, T:
AbbVie Inc, N Chicago, IL USA
Michelena, N:
AbbVie Inc, N Chicago, IL USA
de Lamadrid, RS:
AbbVie Inc, N Chicago, IL USA
Dignass, A:
Goethe Univ, Agaplesion Markus Hosp, Dept Med 1, Frankfurt, Germany
Gomollón, F:
Hosp Clin Univ Lozano Blesa, IIS Aragon, Avda San Juan Bosco 15, Zaragoza 50009, Spain
hybrid, Green Published
|